Matinas Biopharma (MTNB) Competitors $1.68 -0.02 (-0.89%) As of 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. RLMD, OKUR, MDCX, MRSN, XLO, MURA, RNXT, RANI, HYPD, and JATTShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Relmada Therapeutics (RLMD), OnKure Therapeutics (OKUR), Medicus Pharma (MDCX), Mersana Therapeutics (MRSN), Xilio Therapeutics (XLO), Mural Oncology (MURA), RenovoRx (RNXT), Rani Therapeutics (RANI), Hyperion DeFi (HYPD), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors Relmada Therapeutics OnKure Therapeutics Medicus Pharma Mersana Therapeutics Xilio Therapeutics Mural Oncology RenovoRx Rani Therapeutics Hyperion DeFi JATT Acquisition Matinas Biopharma (NYSE:MTNB) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation. Is MTNB or RLMD more profitable? Matinas Biopharma's return on equity of -123.06% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Relmada Therapeutics N/A -223.17%-180.41% Do analysts rate MTNB or RLMD? Relmada Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 208.64%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do institutionals and insiders hold more shares of MTNB or RLMD? 11.8% of Matinas Biopharma shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 4.6% of Matinas Biopharma shares are owned by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, MTNB or RLMD? Relmada Therapeutics is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas BiopharmaN/AN/A-$22.94M-$3.89-0.43Relmada TherapeuticsN/AN/A-$79.98M-$2.22-0.73 Does the media favor MTNB or RLMD? In the previous week, Relmada Therapeutics had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for Matinas Biopharma. Relmada Therapeutics' average media sentiment score of -0.44 beat Matinas Biopharma's score of -1.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Matinas Biopharma Negative Relmada Therapeutics Neutral Which has more volatility and risk, MTNB or RLMD? Matinas Biopharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. SummaryRelmada Therapeutics beats Matinas Biopharma on 8 of the 13 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$8.52M$825.34M$5.78B$21.27BDividend YieldN/A4.84%6.67%3.52%P/E Ratio-0.351.1375.8629.52Price / SalesN/A26.55556.2149.54Price / CashN/A19.5637.1124.13Price / Book0.386.7611.434.54Net Income-$22.94M-$4.20M$3.29B$999.70M7 Day Performance-7.97%-0.11%0.61%0.35%1 Month Performance80.11%9.76%6.90%5.47%1 Year PerformanceN/A25.99%59.44%15.40% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas Biopharma0.3065 of 5 stars$1.68-0.9%N/AN/A$8.52MN/A-0.3530Short Interest ↑Gap DownRLMDRelmada Therapeutics4.1427 of 5 stars$1.15+2.6%$5.00+335.2%-46.3%$37.67MN/A-0.5110News CoverageGap DownOKUROnKure Therapeutics2.8811 of 5 stars$2.76+0.2%$32.33+1,073.2%N/A$37.29MN/A-0.57N/AMDCXMedicus Pharma1.7619 of 5 stars$2.08+7.2%$23.50+1,029.8%N/A$37.07MN/A-1.55N/AAnalyst ForecastMRSNMersana Therapeutics3.7625 of 5 stars$7.37+0.7%$56.60+668.0%-80.2%$36.78M$40.50M-0.50150XLOXilio Therapeutics2.4827 of 5 stars$0.70-0.2%$3.00+329.2%-12.1%$36.23M$6.34M-0.9270MURAMural Oncology3.578 of 5 stars$2.09+1.2%$12.00+475.5%-34.3%$36.11MN/A-0.24119RNXTRenovoRx2.2255 of 5 stars$0.99+3.5%$7.50+654.5%+17.8%$36.10M$40K-2.596Negative NewsShort Interest ↑Gap UpRANIRani Therapeutics3.2647 of 5 stars$0.49-3.4%$7.33+1,387.5%-83.7%$35.43M$1.03M-0.54110Positive NewsShort Interest ↓Gap UpHYPDHyperion DeFi0.1213 of 5 stars$6.20+1.6%$2.00-67.7%-85.8%$35.28M$60K-0.1140JATTJATT AcquisitionN/A$2.04-3.8%N/A-50.2%$35.19MN/A0.003High Trading Volume Related Companies and Tools Related Companies RLMD Alternatives OKUR Alternatives MDCX Alternatives MRSN Alternatives XLO Alternatives MURA Alternatives RNXT Alternatives RANI Alternatives HYPD Alternatives JATT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
